journal article·2011-02

A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin αvβ3 and tenascin-C proteins

Hae Young Ko, Kyung-Ju Choi, Chang Hyun Lee, Soonhag Kim

Biomaterials· Volume 32· Issue 4
Publisher page

Abstract

Molecular imaging of cancers has been characterized based on the sensitivity and selectivity of a single cancer probe targeting a cancer biomarker of a specific cancer cell line. Here, we designed a multimodal nanoparticle-based Simultaneously Multiple Aptamers and RGD Targeting (SMART) cancer probe targeting multiple cancer biomarkers to enhance the specificity and signal sensitivity for various cancers. Transmission electron microscopy revealed that the multimodal SMART cancer probe was spheric and well dispersed. Fluorescence, radioisotope, and magnetic resonance analysis demonstrated that the SMART cancer probe simultaneously targeting the nucleolin, integrin α(v)β(3) and Tnc proteins had dramatically enhanced specificity and signal intensity when used to target cancers from C6, NPA, DU145, HeLa and A549 cells when compared with single cancer probes conjugated with AS1411, RGD or TTA1 targeting a single cancer biomarker. The results demonstrated that the SMART cancer probe will be useful for the diagnosis of different cancers as a cancer master probe.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · Nanoplatforms for cancer theranostics · Click Chemistry and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (35)

Show source-provided references
1. Molecular imaging in cancer10.1126/science.1125949 ↗
2. Nanocrystal targeting in vivo10.1073/pnas.152463399 ↗
3. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects10.1021/nl052405t ↗
4. Bioimaging of nucleolin aptamer-containing 5-(N-benzylcarboxyamide)-2′-deoxyuridine more capable of specific binding to targets in cancer cells
5. (68)Ga-Labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer10.1021/jm100623e ↗
6. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer10.1158/1078-0432.CCR-08-2635 ↗
7. Biofunctionalized, phosphonate-grafted, ultrasmall iron oxide nanoparticles for combined targeted cancer therapy and multimodal imaging10.1002/smll.200901219 ↗
8. Is radionuclide transmission scanning obsolete for dual-modality PET/CT systems?10.1007/s00259-006-0337-6 ↗
9. Point/counterpoint. Simultaneous PET/MR will replace PET/CT as the molecular multimodality imaging platform of choice10.1118/1.2732493 ↗
10. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation
11. Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma10.1038/sj.bjc.6602668 ↗
12. Novel antitenascin antibody with increased tumour localisation for pretargeted antibody-guided radioimmunotherapy (PAGRIT)10.1038/sj.bjc.6600818 ↗
13. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery10.1021/jm049165z ↗
14. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo10.1073/pnas.0601755103 ↗
15. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer10.2967/jnumed.109.069880 ↗
16. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer10.1200/JCO.2005.04.937 ↗
17. Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture10.1016/j.chembiol.2005.11.007 ↗
18. Peptide-based probes for cancer imaging10.2967/jnumed.108.053041 ↗
19. PET imaging of CCND1 mRNA in human MCF7 estrogen receptor positive breast cancer xenografts with oncogene-specific [64Cu]chelator-peptide nucleic acid-IGF1 analog radiohybridization probes10.2967/jnumed.107.042499 ↗
20. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography10.1158/0008-5472.CAN-07-1026 ↗
21. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody10.1016/S0140-6736(95)92839-1 ↗
22. Characterization of anti-NF-kappaB RNA aptamer-binding specificity in vitro and in the yeast three-hybrid system10.1093/nar/gkp670 ↗
23. Fabrication and characterization of RNA aptamer microarrays for the study of protein-aptamer interactions with SPR imaging10.1093/nar/gkl738 ↗
24. Aptamer therapeutics advance10.1016/j.cbpa.2006.03.015 ↗
25. Structure, recognition and adaptive binding in RNA aptamer complexes10.1006/jmbi.1997.1281 ↗
26. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease10.1038/nrd1955 ↗
27. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells10.1158/0008-5472.CAN-07-5723 ↗
28. Aptamer-based detection of epithelial tumor marker mucin 1 with quantum dot-based fluorescence readout10.1021/ac901223q ↗
29. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors10.1038/nbt.1560 ↗
30. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment10.1073/pnas.2136683100 ↗
31. Multiplex imaging of single tumor cells using quantum-dot-conjugated aptamers10.1002/smll.200900848 ↗
32. In vitro derby imaging of cancer biomarkers using quantum dots10.1002/smll.200801580 ↗
33. Tumor targeting by an aptamer
34. Clinical translation of angiogenesis inhibitors10.1038/nrc905 ↗
35. Development of a quadruple imaging modality by using nanoparticles10.1002/chem.200900344 ↗